3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
NETWORK
1
Study Type
Observational
6
Interventional
1
Sponsor
Cancer Type
CNS
17
Endocrine
2
Breast
2
Thoracic
1
Other hematologic neoplasm
1
Other
1
Lymphoid
1
Head & Neck
1
Genitourinary
1
Classical hematology
1
Conditions
Anemia, Refractory, with Excess of Blasts
255
Myelodysplastic Syndromes
228
Leukemia, Myeloid, Acute
228
Anemia
212
Leukemia
205
Precursor Cell Lymphoblastic Leukemia-Lymphoma
168
Leukemia, Myelomonocytic, Chronic
145
Neoplasms
142
Leukemia, Lymphocytic, Chronic, B-Cell
116
Myeloproliferative Disorders
114
Multiple Myeloma
113
Lymphoma, Non-Hodgkin
105
Thrombocytopenia
100
Lymphoma
98
Hodgkin Disease
91
Anemia, Refractory
81
Congenital Abnormalities
77
Anemia, Aplastic
77
Venous Thromboembolism
76
Primary Myelofibrosis
76
Lymphoma, Follicular
73
Leukemia, Myeloid, Chronic-Phase
70
Blast Crisis
67
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
65
Leukemia, Myeloid, Accelerated Phase
64
Lymphoma, Mantle-Cell
63
Febrile Neutropenia
62
Myelodysplastic-Myeloproliferative Diseases
58
Hematologic Neoplasms
56
Burkitt Lymphoma
56
Interventions
Medical Marijuana
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Epilepsy
×
Classical hematology
×
Clear all
NCT03944447
2022-06-02
OMNI-Can
OMNI Medical Services, LLC
Phase 2
Unknown
200,000 enrolled